Evidence map›Paper›PMID 37393702›Full record

ArticleClinical neurology and neurosurgery2023

Predictors of seizure outcomes of autoimmune encephalitis: A clinical and morphometric quantitative analysis study.

Claude Steriade, Palak S Patel, Jennifer Haynes, Ninad Desai, Nader Daoud, Heidi Yuan, Helen Borges, Heath Pardoe

Abstract read
In one paragraph

Article in Clinical neurology and neurosurgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Autoimmune encephalitis-associated epilepsy.Nature reviews. Neurology · 2025
    Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Claude SteriadeNYU Comprehensive Epilepsy Center, NYU Langone Medical Center, New York City, NY, USA. Electronic address: claude.steriade@nyulangone.org.
Palak S PatelNYU Langone Medical Center, NY, USA and JFK Hackensack Meridian Health, NJ, USA. ORCID # which is 0000-0001-3023
Jennifer HaynesNYU Comprehensive Epilepsy Center, NYU Langone Medical Center, New York City, NY, USA; Virginia Commonwealth University, Richmond, VA, USA.
Ninad DesaiNYU Comprehensive Epilepsy Center, NYU Langone Medical Center, New York City, NY, USA; Hartford Healthcare Medical Group, CT, USA.
Nader DaoudNYU Comprehensive Epilepsy Center, NYU Langone Medical Center, New York City, NY, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Heidi YuanNYU Comprehensive Epilepsy Center, NYU Langone Medical Center, New York City, NY, USA; University of Illinois College of Medicine, Chicago, IL, USA.
Helen BorgesNYU Comprehensive Epilepsy Center, NYU Langone Medical Center, New York City, NY, USA.
Heath PardoeNYU Comprehensive Epilepsy Center, NYU Langone Medical Center, New York City, NY, USA; The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia.

Funding

Institutional Career DevelopmentKL2TR001446 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PILLINGER, MICHAEL · 2015 to 2025
$6.7M
NCATS NIH HHS KL2 TR001446
6 · The paper itself

Abstract

objectiveAutoimmune encephalitis can be followed by treatment-resistant epilepsy. Understanding its predictors and mechanisms are crucial to future studies to improve autoimmune encephalitis outcomes. Our objective was to determine the clinical and imaging predictors of postencephalitic treatment-resistant epilepsy.

methodsWe performed a retrospective cohort study (2012-2017) of adults with autoimmune encephalitis, both antibody positive and seronegative but clinically definite or probable. We examined clinical and imaging (as defined by morphometric analysis) predictors of seizure freedom at long term follow-up.

resultsOf 37 subjects with adequate follow-up data (mean 4.3 yrs, SD 2.5), 21 (57 %) achieved seizure freedom after a mean time of 1 year (SD 2.3), and one third (13/37, 35 %) discontinued ASMs. Presence of mesial temporal hyperintensities on the initial MRI was the only independent predictor of ongoing seizures at last follow-up (OR 27.3, 95 %CI 2.48-299.5). Morphometric analysis of follow-up MRI scans (n = 20) did not reveal any statistically significant differences in hippocampal, opercular, and total brain volumes between patients with postencephalitic treatment-resistant epilepsy and those without. SIGNIFICANCE: Postencephalitic treatment-resistant epilepsy is a common complication of autoimmune encephalitis and is more likely to occur in those with mesial temporal hyperintensities on acute MRI. Volume loss in the hippocampal, opercular, and overall brain on follow-up MRI does not predict postencephalitic treatment-resistant epilepsy, so additional factors beyond structural changes may account for its development.

Indexed as

Autoimmune Diseases of the Nervous SystemEpilepsyAdultEncephalitisHashimoto DiseaseHumansMagnetic Resonance ImagingRetrospective StudiesSeizuresTreatment OutcomeEncephalitisMorphometric analysisMRIOutcomesQuantitative imaging

Identifiers

PMID37393702
PMCPMC10530025

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.